JAK3

Oncogene
Tyrosine-protein kinase JAK3 UniProt accession P52333

Non-receptor tyrosine kinase involved in various processes such as cell growth, development, or differentiation. Mediates essential signaling events in both innate and adaptive immunity and plays a crucial role in hematopoiesis during T-cells development. In the cytoplasm, plays a pivotal role in signal transduction via its association with type I receptors sharing the common subunit gamma such as IL2R, IL4R, IL7R, IL9R, IL15R and IL21R.

Following ligand binding to cell surface receptors, phosphorylates specific tyrosine residues on the cytoplasmic tails of the receptor, creating docking sites for STATs proteins. Subsequently, phosphorylates the STATs proteins once they are recruited to the receptor. Phosphorylated STATs then form homodimer or heterodimers and translocate to the nucleus to activate gene transcription.

For example, upon IL2R activation by IL2, JAK1 and JAK3 molecules bind to IL2R beta (IL2RB) and gamma chain (IL2RG) subunits inducing the tyrosine phosphorylation of both receptor subunits on their cytoplasmic domain. Then, STAT5A and STAT5B are recruited, phosphorylated and activated by JAK1 and JAK3. Once activated, dimerized STAT5 translocates to the nucleus and promotes the transcription of specific target genes in a cytokine-specific fashion

Source: UniProt

Interacts with STAM2 and MYO18A (PubMed:10899310). Interacts with SHB (PubMed:12200137). Interacts with CD69 (By similarity)

Source: UniProt
Endomembrane system — Peripheral membrane protein, Cytoplasm
Source: UniProt

In NK cells and an NK-like cell line but not in resting T-cells or in other tissues. The S-form is more commonly seen in hematopoietic lines, whereas the B-form is detected in cells both of hematopoietic and epithelial origins

Source: UniProt

Possesses two phosphotransferase domains. The second one probably contains the catalytic domain (By similarity), while the presence of slight differences suggest a different role for domain 1

Source: UniProt
  • Severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-negative (T(-)B(+)NK(-) SCID)

    A form of severe combined immunodeficiency (SCID), a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients present in infancy recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development.

Source: UniProt
  • Interleukin-7 signaling
  • Signaling by ALK
  • RAF/MAP kinase cascade
  • Interleukin-4 and Interleukin-13 signaling
  • Interleukin-20 family signaling
  • Interleukin-15 signaling
  • Interleukin-9 signaling
  • Interleukin-2 signaling
  • Interleukin-21 signaling
  • Interleukin receptor SHC signaling
  • Potential therapeutics for SARS
Source: Reactome via UniProt

Mutations

Cancer Type Mutation Percentage
Central Nervous System Astrocytoma Grade Iv 0.95%
Lung Adenocarcinoma 1.22%
Lung Small Cell Carcinoma 0.59%
Lung Squamous Cell Carcinoma 1.36%
Oesophagus Squamous Cell Carcinoma 0.94%
Pancreas Ductal Carcinoma 0.41%

Synthetic Lethal Network

Genes with an experimentally identified or computationally predicted synthetic-lethal relationship to JAK3, aggregated across our SSL data sources. Click any partner node to view that gene’s page.

Nodes and edges are coloured by the SSL data source. Partners appearing in more than one source are shown in grey.

BioGRID SLOrth SynLethDB MexDrugs Multi-source
Sources: BioGRID, SLOrth, SynLethDB, MexDrugs

Clinical Trials

Total Trials Found: 13

NCT ID Condition Brief Title Phase Status
NCT01754935 Rheumatoid Arthritis A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 Inhibitor PHASE2 COMPLETED
NCT00483756 Kidney Transplantation Study of a JAK3 Inhibitor for the Prevention of Acute Rejection in Kidney Transplant Patients PHASE2 COMPLETED
NCT00550446 Arthritis, Rheumatoid A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis PHASE2 COMPLETED
NCT05549934 Cicatricial Alopecia Ritlecitinib for Cicatricial Alopecia PHASE2 COMPLETED
NCT00006319 Wiskott- Aldrich Syndrome, ADA Deficient SCID Molecular and Clinical Studies of Primary Immunodeficiency Diseases N/A UNKNOWN
NCT06209138 Vitiligo 5-fluorouracil for Treatment of Stable Vitiligo NA COMPLETED
NCT00263328 Kidney Transplantation Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient PHASE2 COMPLETED
NCT00556257 Kidney Transplantation Study Of JAK3 Inhibitor For The Prevention Of Acute Rejection In Kidney Transplant Patients PHASE2 WITHDRAWN
NCT05128058 Healthy A Target Occupancy Study With Ritlecitinib. PHASE1 COMPLETED
NCT03601819 Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Chronic Lymphocytic Leukemia, Lymphoproliferative Disorders, Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma, Mantle Cell Lymphoma Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders PHASE1 TERMINATED